Radforsk has made a significant impact on cancer research and treatment in Norway. Since our establishment in 1987, we have focused on the commercialisation of cancer research in order to contribute to better treatment for each individual cancer patient.
To pursue our goal of better cancer treatment, we invest in infrastructure through Radforsk Innovation and in companies through Radforsk Invest, and we link private enterprises with research environments. Our investments and innovation activities have resulted in several companies being listed, and in substantial growth for companies engaged in cancer treatment and related products on the global market.
So far, Radforsk has allocated NOK 237 million from our profits to research and strategic projects at Oslo University Hospital.
Radforsk Invest's role goes far beyond traditional financing, and we put a lot of effort into developing our portfolio companies. We are investors, entrepreneurs and developers of companies. Groundbreaking new cancer treatment takes time to develop, and our 'evergreen' model means that we have a long-term perspective. We contribute both strategically and operationally before, during and after companies are established. At Radforsk Invest, we take a global approach to our investments.
Radforsk Innovation's role includes building ecosystems and infrastructure such as Oslo Cancer Cluster, Oslo Cancer Cluster Incubator and Oslo Cancer Cluster Innovation Park, which promote innovation and research on cancer treatment.
The patient perspective is the core of Radforsk's philosophy. Our job is to bring new cancer treatment from the laboratory to the market, and to the patients who need it. This patient focus is reflected in our support for the development of therapies and technologies that address as yet unmet medical needs.
-
Bransje
-
Bioteknologisk forskning
-
Bedriftsstørrelse
-
2–10 ansatte
-
Hovedkontor
-
Oslo
-
Type
-
Ideell organisasjon
-
Grunnlagt
-
1987
-
Spesialiteter
-
oncology, investetment, biotechnology
